Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – 9,10-seco- cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2006-01-24
2006-01-24
Qazi, Sabiha N. (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
9,10-seco- cyclopentanohydrophenanthrene ring system doai
C552S653000
Reexamination Certificate
active
06989377
ABSTRACT:
The present invention relates to therapeutics for the prevention and treatment of vitamin D responsive diseases in humans, as well as other animals, through the use of biologically active vitamin D compounds in combination with at least one other immunomodulatory compound such as interleukin-10, interleukin-4, or a TNFα inhibitor.
REFERENCES:
patent: 4312806 (1982-01-01), Lambert et al.
patent: 4638043 (1987-01-01), Szycher et al.
patent: 5216002 (1993-06-01), Gidda et al.
patent: 5238931 (1993-08-01), Yoshikawa et al.
patent: 5294630 (1994-03-01), Blake et al.
patent: 5368854 (1994-11-01), Rennick
patent: 5391555 (1995-02-01), Marshall et al.
patent: 5446035 (1995-08-01), Neef et al.
patent: 5506213 (1996-04-01), Carson et al.
patent: 5518725 (1996-05-01), Daynes et al.
patent: 5552439 (1996-09-01), Panetta
patent: 5569680 (1996-10-01), Wu
patent: 5583125 (1996-12-01), Steinmeyer et al.
patent: 5643602 (1997-07-01), Ulmius
patent: 5663157 (1997-09-01), Steinmeyer et al.
patent: 5710142 (1998-01-01), Calverley et al.
patent: 5711964 (1998-01-01), Dattagupta et al.
patent: 5716945 (1998-02-01), Grue-Sorensen
patent: 5716946 (1998-02-01), DeLuca et al.
patent: 5756449 (1998-05-01), Andersen et al.
patent: 5756733 (1998-05-01), Hesse et al.
patent: 5786347 (1998-07-01), Hesse et al.
patent: 5792795 (1998-08-01), Buser et al.
patent: 5811562 (1998-09-01), Hesse et al.
patent: 5824313 (1998-10-01), Daynes et al.
patent: 5830505 (1998-11-01), Fischer et al.
patent: 5834016 (1998-11-01), Naeff et al.
patent: 5834021 (1998-11-01), Speirs
patent: 5851548 (1998-12-01), Dattagupta et al.
patent: 5872140 (1999-02-01), Hesse et al.
patent: 5876746 (1999-03-01), Jona et al.
patent: 5877168 (1999-03-01), Miyamoto et al.
patent: 5883271 (1999-03-01), Ono
patent: 5888969 (1999-03-01), Girten et al.
patent: 5889028 (1999-03-01), Sandborn et al.
patent: 5891865 (1999-04-01), DeLuca et al.
patent: 5902806 (1999-05-01), Ikeda et al.
patent: 5905074 (1999-05-01), Schneider
patent: 5929056 (1999-07-01), Mourino et al.
patent: 5932214 (1999-08-01), Lobb et al.
patent: 5932565 (1999-08-01), Grue-Sorensen
patent: 5936105 (1999-08-01), Paaren
patent: 5952317 (1999-09-01), Deluca et al.
patent: 5981597 (1999-11-01), Wu
patent: 6214373 (2001-04-01), Snowden
patent: 6358939 (2002-03-01), Hayes et al.
patent: 6440953 (2002-08-01), DeLuca et al.
patent: 2003/0188756 (2003-10-01), Cantorna
patent: 44 05 545 (1995-08-01), None
patent: 0927721 (1997-12-01), None
patent: WO 96/30326 (1996-10-01), None
patent: WO 98/51644 (1998-11-01), None
patent: WO 98/51678 (1998-11-01), None
patent: WO 01/42205 (2001-06-01), None
Barrat et al. (DN 136339213, CAPLUS, abstract of J. of Experimental Medicine (2002), 195(5), 603-616).
Penna et al. (DN 132:292680, CAPLUS, abstrct of J. of immunology (2000), 164(5): 2405-2411).
Dam et al. (DN 132:146376, CAPLUS, abstract of J. of investigative Dermatology (1999), 113(6), 1082-1089).
DeLuca, Hector et al., “Vitamin D: Its Role and Uses in Immunology,”The FASEB Journal,2001, vol. 15, pp. 2579-2585.
Breese, E. et al., “Interleukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa,”Immunology,1993, vol. 78, pp. 127-131.
Best, W. R. et al., “Development of a Crohn's Disease Activity Index: National Cooperative Crohn's Disease Study,”Gastroenterology,70(3); pp. 439-444 (1976); published by The Williams & Wilkins Co.
Bradford, M. M., A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding,Anal. Biochem.,72; pp. 248-254 (1976).
Schefler, W. C.,Statistics for the Biological Sciences,2ndEd., pp. 214-216; p. A-17 (1979); published by Addison-Wesley Publ. Co., Reading, MA, USA.
Moolenbeek, C. et al., “The ‘Swiss roll’: a simple technique for histological studies of the rodent intestine,”Lab. Anim.,15; pp. 57-59 (1981).
Krawisz, J. E. et al., “Quantitative Assay for Acute Intestinal Inflammation Based on Myeloperoxidase Activity,”Gastroenterology,87; pp. 1344-1350 (1984); published by the American Gastroenterological Association.
Koizumi et al., “Effects of Corticosteroid and 1,24R-Dihydroxy-Vitamin D3Administration on Lymphoproliferation and Autoimmune Disease in MRL/MP-Ipr/Ipr Mice,”Int. Archs Allergy appl. Immun.,77; pp. 396-404 (1985); published by S. Karger AG, Basel.
Ostrem, V.K. et al., “24- and 26-homo-1,25-dihydroxyvitamin D3: Preferential activity in inducing differentiation of human leukemia cells HL-60in vitro,” Proc. Natl. Acad. Sci. USA,84; pp. 2610-2614, May (1987).
Pallone et al., “Activation of peripheral blood and intestinal lamina propria lymphocytes in Crohn's disease.In vivostate of activation andin vitroresponse to stimulation as defined by the expression of early activation antigens,” Gut, 28; pp. 745-753 (1987).
Kaulfersch et al., “Polyclonal Nature of the Intestinal Mucosal Lymphocyte Populations in Inflammatory Bowel Disease,”Gastroenterology,95; pp. 364-370 (1988); published by the American Gastroenterological Association.
Abe et al., “A Synthetic Analogue of Vitamin D3, 22-OXA-1α, 25-Dihydroxyvitamin D3, is a Potent Modulator ofin vivoImmuno-Regulating Activity Without Inducing Hypercalcemia in Mice,”Endocrinology,124(5); pp. 2645-2647 (1989); published by The Endocrine Society.
Norman, A. W., et al., “Structure-Function Studies on Analogues of 1α,25-Dihydroxyvitamin D3: Differential Effects on Leukemic Cell Growth, Differentiation, and Intestinal Calcium Absorption,”Cancer Res.,50; pp. 6857-6864, Nov. 1 (1990).
Okayasu, I. et al., A Novel Method in the Induction of Reliable Experimental Acute and Chronic Ulcerative Colitis in Mice,Gastroenterology,98; pp. 694-702 (1990); published by the American Gastroenterological Association.
Perlman, K. et al., 4-Homologated 1,25-Dihydroxyvitamin D3Compounds: Separation of Calcium and Cell Differentiation Activities,Biochemistry,29(1); pp. 190-196 (1990).
Sonnenberg, A. et al., “Epidemiology of Inflammatory Bowel Disease Among U.S. Military Veterans,”Gastro.,101; pp. 122-130 (1991); published by the American Gastroenterological Association.
Sonnenberg, A. et al., “Geographic Variation of Inflammatory Bowel Disease Within the United States,”Gastro.,100; pp. 143-149 (1991); published by the American Gastroenterological Association.
Uno, H., “Hokuku,”Nippon Jui Chikusan Daigaku Keukya,40; pp. 111-112 (1991).
Binderup, L., “Immunological Properties of Vitamin D Analogues and Metabolites,”Biochemical Pharmacology,43(9); pp. 1885-1892 (1992); published by Pergamon Press Ltd, Great Britain.
Bouillon, R. et al., “Structure Function Analysis of Vitamin D Analogs with C-ring Modifications*,”J. Biol. Chem.,267(5); pp. 3044-3051 (1992); published by The American Society of Biochemistry and Molecular Biology, Inc.
Labuda, M. et al., “Two Hereditary Defects Related to Vitamin D Metabolism Map to the Same Region of Human Chromosome 12q13-14,”,J. Bone Min. Res.,7(12); pp. 1447-1453 (1992); published by Mary Ann.
Lemire, J.M. et al., “Protolongation of the Survival of Murine Cardiac Allografts by the Vitamin D3Analogue 1,25-Dihydroxy-Δ16-Cholecalciferol,”Transplantation,54(4); pp. 762-763, Oct. (1992).
Lillevang, S. T. et al., “Single and combined effects of the vitamin D analogue KH1060 and cyclosporin A on mercuric-chloride-induced autoimmune disease in the BN rat,”Clin. Exp. Immunol.,88; pp. 301-306 (1992).
Schull, M. M. et al., “Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease,”Nature,359; p. 693-699, Oct. 22 (1992).
Sonnenberg, A. et al., “Geography and Inflammatory Bowel Disease,”Gastroenterol.,102; p. 1827 (1992).
Breese, E. et al., “Interleukin-2- and interferon-γ-secreting T cells in normal and diseased human int
Hayes Colleen E.
Nashold Faye E.
Foley & Lardner LLP
Qazi Sabiha N.
Wisconsin Alumni Research Foundation
LandOfFree
Treating vitamin D responsive diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treating vitamin D responsive diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treating vitamin D responsive diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3558691